All articles
NAD+ Injections: Benefits, Safety & Side Effects
Reading time:
9 min
Longevity

Get expert guidance and a personalized care plan designed around you.
Potential Side Effects
Individual responses to NAD+ administration vary. Based on existing animal studies and limited human trials using IV NAD+ or high dose precursors, reported side effects include:
Cardiovascular and Muscle Symptoms: Chest tightness, rapid heart rate, and localized muscle cramping (21).
Gastrointestinal Distress: Abdominal cramping, nausea, and intestinal discomfort (7, 21, 22)
Neurological Effects: Temporary headaches, dizziness, fatigue, anxiety, insomnia, and localized tingling sensations in the jaw, tongue, or arms (22).
Metabolic Findings: Preclinical models using high dosages have noted potential liver strain, methyl group depletion, and changes in glucose sensitivity (7, 12, 23).
How Subcutaneous NAD+ Injection Therapy Works
When prescribed, NAD+ is most commonly administered as a subcutaneous injection into the tissue of the abdomen or outer thigh. Patients may experience mild discomfort or minor localized reactions at the injection site (24). Dosages should always be determined and monitored by a licensed healthcare provider.
Peptide and Coenzyme Safety: Key Considerations
Peptides and specialized coenzymes have more recently gained significant popularity in wellness care (25). While regulatory bodies like the FDA approved nine new peptide therapies in a single year (2023) (26), taking appropriate precautions remains essential:
Watch for Allergic Reactions: Like any therapy, injected compounds can trigger immune responses. Seek immediate medical care if you experience hives, shortness of breath, chest pain, or severe dizziness. Allergies can develop over time even after previous uneventful uses (27-29).
Recognize Animal vs. Human Findings: Results from animal models do not guarantee identical effects or safety profiles in humans. Always discuss investigational therapies with a healthcare professional before starting (30).
Verify Product Sourcing: It’s a good idea to avoid unregulated online vendors. Ensure formulations come from accredited compounding pharmacies that provide a Certificate of Analysis (CoA) verifying 99%+ purity and testing for contaminants (31).
Monitor Injection Sites: Sometimes, mild, temporary redness can occur. However, persistent swelling, hardening, or worsening pain over time requires medical evaluation to rule out infection or hypersensitivity (32).
Always consult a qualified healthcare provider before starting NAD+ or peptide-based therapies. If you are interested in exploring whether these options are appropriate for you, check your eligibility here: Mochi Health Eligibility.
FAQs
What are NAD+ injections?
NAD+ injections deliver nicotinamide adenine dinucleotide directly into the body through a subcutaneous injection. Unlike oral supplements, injections bypass digestion for more direct absorption.
What are the side effects of NAD+ injections?
Reported side effects from NAD+ or high-dose precursor studies include nausea, abdominal cramping, chest tightness, headaches, dizziness, and localized tingling. In preclinical studies, high dosages have also been associated with liver enzyme changes and shifts in glucose sensitivity.
Are NAD+ injections safe?
Human safety data on direct NAD+ injections is limited. While no significant adverse events were reported in small IV infusion studies, researchers noted signs of liver strain at high doses. Formulations should come from accredited compounding pharmacies with verified purity testing.
How are NAD+ injections different from IV NAD+ therapy?
IV therapy delivers NAD+ directly into the bloodstream for immediate 100% bioavailability but requires a clinical setting and can take several hours. Subcutaneous injections absorb gradually for steadier levels and can be done at home. Both bypass the first-pass liver metabolism that occurs with oral supplements.
References:
Alegre, G. F. S., & Pastore, G. M. (2023). NAD+ precursors nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR): Potential dietary contribution to health. Current Nutrition Reports, 12(3), 445–464. https://pmc.ncbi.nlm.nih.gov/articles/PMC10240123/
Shade, C. (2020). The science behind NMN–A stable, reliable NAD+ activator and anti-aging molecule. Integrative Medicine: A Clinician's Journal, 19(1), 12–14. https://pmc.ncbi.nlm.nih.gov/articles/PMC7238909/
Gallagher, C., & Emmanuel, O. O. (2026). NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Research Reviews, 116, Article 103057. https://www.sciencedirect.com/science/article/pii/S1568163726000498
Bloomer, R. J., Timmcke, J. Q., & Ramanathan, C. (2025). Use of the dietary supplements NR and NMN to increase nicotinamide adenine dinucleotide, impact mitochondrial function, and improve metabolic health. Clinical Bioenergetics, 1(2), Article 9. https://doi.org/10.3390/clinbioenerg1020009
Braidy, N., & Liu, Y. (2020). NAD+ therapy in age-related degenerative disorders: A benefit/risk analysis. Experimental Gerontology, 132, Article 110831. https://www.sciencedirect.com/science/article/abs/pii/S0531556519307582
Davis, I., & Liu, A. (2015). What is the tryptophan kynurenine pathway and why is it important to neurotherapeutics? Expert Review of Neurotherapeutics, 15(7), 719–721. https://pmc.ncbi.nlm.nih.gov/articles/PMC4482796/
She, J., Sheng, R., & Qin, Z.-H. (2021). Pharmacology and potential implications of nicotinamide adenine dinucleotide precursors. Aging and Disease, 12(8), 1879–1897. https://pmc.ncbi.nlm.nih.gov/articles/PMC8612620/
Radenkovic, D., Reason, & Verdin, E. (2020). Clinical Evidence for Targeting NAD Therapeutically. Pharmaceuticals, 13(9), 247. https://www.mdpi.com/1424-8247/13/9/247
Bhasin, S., Seals, D., Migaud, M., Musi, N., & Baur, J. A. (2023). Nicotinamide adenine dinucleotide in aging biology: Potential applications and many unknowns. Endocrine Reviews, 44(6), 1047–1073. https://doi.org/10.1210/endrev/bnad019
Xie, N., Zhang, L., Gao, W., Huang, C., Huber, P. E., Zhou, X., Li, C., Shen, G., & Zou, B. (2020). NAD+ metabolism: Pathophysiologic mechanisms and therapeutic potential. Signal Transduction and Targeted Therapy, 5(1), Article 227. https://doi.org/10.1038/s41392-020-00311-7
Yaku, K., Palikhe, S., Iqbal, T., Hayat, F., Watanabe, Y., Fujisaka, S., Izumi, H., Yoshida, T., Karim, M., Uchida, H., Nawaz, A., Tobe, K., Mori, H., Migaud, M. E., & Nakagawa, T. (2025). Nicotinamide riboside and nicotinamide mononucleotide facilitate NAD+ synthesis via enterohepatic circulation. Science Advances, 11(12), Article eadr1538. https://doi.org/10.1126/sciadv.adr1538
Grant, R., Berg, J., Mestayer, R., Braidy, N., Bennett, J., Broom, S., & Watson, J. (2019). A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD+. Frontiers in Aging Neuroscience, 11, Article 257. https://doi.org/10.3389/fnagi.2019.00257
Nikiforov, A., Dölle, C., Niere, M., & Ziegler, M. (2011). Pathways and subcellular compartmentation of NAD biosynthesis in human cells: From entry of extracellular precursors to mitochondrial NAD generation. Journal of Biological Chemistry, 286(24), 21767–21778. https://doi.org/10.1074/jbc.M110.213298
Pittelli, M., Felici, R., Pitozzi, V., Giovannelli, L., Bigagli, E., Cialdai, F., ... & Chiarugi, A. (2011). Pharmacological effects of exogenous NAD on mitochondrial bioenergetics, DNA repair, and apoptosis. Molecular pharmacology, 80(6), 1136-1146. https://molpharm.aspetjournals.org/article/S0026-895X(24)03359-5/abstract
Zhang, Y., Wang, B., Fu, X., Guan, S., Han, W., Zhang, J., Gan, Q., Fang, W., Ying, W., & Qu, X. (2016). Exogenous NAD+ administration significantly protects against myocardial ischemia/reperfusion injury in rat model. American Journal of Translational Research, 8(8), 3342–3350. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009387/
Takaso, Y., Noda, M., Hattori, T., Roboon, J., Hatano, M., Sugimoto, H., Brenner, C., Yamamoto, Y., Okamoto, H., Higashida, H., Ito, M., Yoshizaki, T., & Hori, O. (2020). Deletion of CD38 and supplementation of NAD+ attenuate axon degeneration in a mouse facial nerve axotomy model. Scientific Reports, 10(1), Article 17795. https://doi.org/10.1038/s41598-020-73984-3
Slama, N., Abdellatif, A., Bahria, K., Gasmi, S., Khames, M., Hadji, A., Birkmayer, G., Oumouna, M., Amrani, Y., & Benachour, K. (2024). NADH intraperitoneal injection prevents lung inflammation in a BALB/C mice model of cigarette smoke-induced chronic obstructive pulmonary disease. Cells, 13(10), Article 881. https://doi.org/10.3390/cells13100881
Bittner, B., Richter, W., & Schmidt, J. (2018). Subcutaneous administration of biotherapeutics: An overview of current challenges and opportunities. BioDrugs, 32(5), 425–440. https://doi.org/10.1007/s40259-018-0295-0
Jin, J.-F., Zhu, L.-L., Chen, M., Xu, H.-M., Wang, H.-F., Feng, X.-Q., Zhu, X.-P., & Zhou, Q. (2015). The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. Patient Preference and Adherence, 9, 923–942. https://doi.org/10.2147/PPA.S87271
Price, G., & Patel, D. A. (2023). Drug bioavailability. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK557852/
Reyna, K., Heinzen, G., Patel, N., Ritter, M., Siojo, A., Legere, H., & Pojednic, R. (2026). Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): A retrospective tolerability pilot study in a real-world setting. Frontiers in Aging, 7, Article 1652582. https://doi.org/10.3389/fragi.2026.1652582
Gindri, I. de M., Ferrari, G., Pinto, L. P. S., Bicca, J., dos Santos, I. K., Dallacosta, D., & Roesler, C. R. de M. (2024). Evaluation of safety and effectiveness of NAD in different clinical conditions: A systematic review. American Journal of Physiology-Endocrinology and Metabolism, 326(4), E417–E427. https://doi.org/10.1152/ajpendo.00242.2023
Hwang, E. S., & Song, S. B. (2020). Possible adverse effects of high-dose nicotinamide: Mechanisms and safety assessment. Biomolecules, 10(5), Article 687. https://doi.org/10.3390/biom10050687
Kashat, E. (2026, June 8). NAD injections: How they work and what providers should know. MediVera Compounding Pharmacy. https://mediverarx.com/nad-injections-guide/
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022). Therapeutic peptides: Current applications and future directions. Signal Transduction and Targeted Therapy, 7(1), Article 48. https://doi.org/10.1038/s41392-022-00904-4
de la Torre, B. G., & Albericio, F. (2024). The pharmaceutical industry in 2023: An analysis of FDA drug approvals from the perspective of molecules. Molecules, 29(3), Article 585. https://doi.org/10.3390/molecules29030585
Shankar, G., Arkin, S., Cocea, L., Devanarayan, V., Kirshner, S., Kromminga, A., Quarmby, V., Richards, S., Schneider, C. K., Subramanyam, M., Swanson, S., Verthelyi, D., & Yim, S. (2014). Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides—Harmonized terminology and tactical recommendations. The AAPS Journal, 16(4), 658–673. https://doi.org/10.1208/s12248-014-9599-2
Chu, M.-T., Chang, W.-C., Pao, S.-C., & Hung, S.-I. (2023). Delayed drug hypersensitivity reactions: Molecular recognition, genetic susceptibility, and immune mediators. Biomedicines, 11(1), Article 177. https://doi.org/10.3390/biomedicines11010177
Yaneva, M., Handjieva-Darlenska, T., Kazandjieva, J., & Darlenski, R. (2023). Delayed type hypersensitivity injection site reaction and tolerance induction to liraglutide for the treatment of obesity. JAAD Case Reports, 38, 100–101. https://doi.org/10.1016/j.jdcr.2023.06.010
Pound, P., & Bracken, M. B. (2014). Is animal research sufficiently evidence based to be a cornerstone of biomedical research? BMJ, 348, g3387. https://doi.org/10.1136/bmj.g3387
U.S. Food and Drug Administration. (2026, May 14). Bulk drug substances used in compounding under Section 503A of the FD&C Act. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
Freibott, C. E., Phillips, K. T., Anderson, B. J., Stewart, C., Liebschutz, J. M., & Stein, M. D. (2022). Under the skin: The relationship between subcutaneous injection and skin infections among people who inject drugs. Journal of Addiction Medicine, 16(2), 164–168. https://doi.org/10.1097/ADM.0000000000000844
Disclaimer: This article is for educational purposes only and should not be considered medical advice. The information provided does not constitute recommendations for treatment. Always consult with your healthcare provider about your specific situation, symptoms, and treatment options.
Share this post
Longevity
More articles












